通讯作者: 刘永利, liuyongli2008@126.com

DOI：10.12201/bmr.202503.00087

Analysis of 237 cases of thyroid related adverse reactions induced by lithium carbonate

• 摘要：摘要 目的 探讨碳酸锂致甲状腺不良反应（ADR）的规律和特点，为临床合理用药提供参考。方法 检索国家药品不良反应监测系统中碳酸锂所致甲状腺ADR病例报告，对患者性别与年龄、用药原因、联合用药、给药剂量、甲状腺ADR临床表现等进行回顾性分析。结果 碳酸锂致甲状腺ADR报告共237例，男女比为1:1.7，20～29岁年龄组频数较高，说明书剂量范围内用药比例为97.8%，联合使用的药品按种类统计最多的是精神障碍用药，ADR出现时间多为服药后10～30d。甲状腺ADR主要临床表现为甲状腺功能减退、甲状腺肿、甲状腺功能亢进。结论 碳酸锂致甲状腺ADR多在治疗剂量下发生，与患者性别、年龄、联合用药等因素相关。临床医师、药师应掌握碳酸锂所致甲状腺的规律和特点，及时发现和治疗ADR，为患者用药安全提供保障。

  关键词： 碳酸锂；甲状腺激素；甲状腺功能减退；甲状腺肿大；甲状腺功能亢进；不良反应；安全性; ; ; ; ; ; 

   

  Abstract: Abstract Objective Investigate the regularity and characteristics of lithium carbonate-induced thyroid adverse reactions ( ADR ), to provide reference for clinical rational drug use. Methods The case reports of thyroid ADR caused by lithium carbonate in the National Adverse Drug Reaction Monitoring System were retrieved, and the gender and age of patients, medication reasons, combined medication, dosage and clinical manifestations of thyroid ADR were retrospectively analyzed. Results A total of 237 cases of thyroid ADRs caused by lithium carbonate were reported, the ratio of male to female was 1:1.7, the frequency was higher in the age group of 20 to 29 years, and the proportion of drug use within the range of instruction dosage was 97.8%. According to the statistics of drugs used in combination, the most drugs were drugs for mental disorders, and the time of ADR occurrence was mostly 10 to 30 days after taking the drug. The main clinical manifestations of thyroid ADR were hypothyroidism, goiter and hyperthyroidism. Conclusion Lithium carbonate-induced thyroid ADR mostly occurred at the therapeutic dose, which was related to the patient s gender, age, combined medication and other factors. Clinicians and pharmacists should master the rules and characteristics of thyroid caused by lithium carbonate, timely detect and treat ADR, to provide guarantee for the safety of patients medication.

  Key words: Lithium carbonate; thyroid hormone; hypothyroidism; goiter enlargement; hyperthyroidism; adverse reactions; safety

  提交时间：2025-03-31

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 范玲, 朱晓静. 我院281例药物性肝损伤不良反应分析. 2024. doi: 10.12201/bmr.202412.00015

  王培培, 贾贝, 戴媛媛. 信迪利单抗致酮症酸中毒伴心肌炎、肌炎1例. 2024. doi: 10.12201/bmr.202411.00022

  黄秋玲, 郁峰, 邹小杰, 徐震. 注意缺陷多动障碍儿童的多动行为与血清促甲状腺激素水平的关系. 2024. doi: 10.12201/bmr.202411.00024

  陈海峰, 钱韵. 免疫检查点抑制剂相关不良反应：临床表现与发生机制. 2025. doi: 10.12201/bmr.202502.00010

  王学斐, 陈曼曼, 滕玉欣, 曾波涛. 青少年抑郁症自伤自杀行为与非酶类抗氧化物及甲状腺激素水平分析. 2024. doi: 10.12201/bmr.202412.00022

  周圆, 刘静, 潘亚雯, 任政. 机器人甲状腺切除术在甲状腺癌治疗研究进展. 2024. doi: 10.12201/bmr.202411.00030

  陈龙满, 王霞, 钱锐, 马迪. 基于内经阴阳理论探讨亚急性甲状腺炎的治疗. 2025. doi: 10.12201/bmr.202503.00083

  王凯, 翁思颖, 周建扬. 基于“木土同病”理论论治甲状腺功能亢进. 2025. doi: 10.12201/bmr.202503.00037

  李威, 耿中利, 昂沙尔·苏来曼. 腔镜甲状腺癌手术中神经监测技术的演进. 2024. doi: 10.12201/bmr.202411.00051

  杨雷, 周梦倩, 汤铜. 术前淋巴结超声特征对甲状腺癌颈侧区淋巴结转移风险的预测. 2024. doi: 10.12201/bmr.202410.00035

• 序号	提交日期	编号	操作
  1	2025-03-03	bmr.202503.00087V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论